PANGEN BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,270 KRW | -.--% |
|
+10.97% | -8.87% |
| Sales 2021 | 7.94B 5.8M 484M | Sales 2022 | 6.5B 4.75M 396M | Capitalization | 69.4B 50.73M 4.23B |
|---|---|---|---|---|---|
| Net income 2021 | -3.31B -2.42M -202M | Net income 2022 | -4.49B -3.29M -274M | EV / Sales 2021 | 11.9 x |
| Net cash position 2021 | 5.4B 3.95M 329M | Net cash position 2022 | 835M 610K 50.9M | EV / Sales 2022 | 10.5 x |
| P/E ratio 2021 |
-28.9
x | P/E ratio 2022 |
-15.4
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 63.73% |
More Fundamentals
* Assessed data
More news
| 1 week | +10.97% | ||
| Current month | +0.16% | ||
| 1 month | +0.16% | ||
| 3 months | +1.62% | ||
| 6 months | +30.35% | ||
| Current year | -8.87% |
1 week
5 570.00
6 390.00
1 month
5 500.006 770.00
Current year
5 500.006 920.00
1 year
3 930.006 920.00
3 years
3 930.0012 200.00
5 years
3 930.0012 950.00
10 years
3 930.0025 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Seung Yoon
CEO | Chief Executive Officer | 63 | 29/10/29 |
Jae-Hong Jang
DFI | Director of Finance/CFO | 58 | 01/10/01 |
Jung-Soo Park
CTO | Chief Tech/Sci/R&D Officer | 54 | 29/10/29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | - | |
Jae-Seung Yoon
CEO | Chief Executive Officer | 63 | 29/10/29 |
| 58 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/24/02 | 5,950 | -5.10% | 11,445 |
| 30/24/30 | 6,270 | -.--% | 12,027 |
| 29/24/29 | 6,270 | +3.47% | 14,873 |
| 26/24/26 | 6,060 | +1.17% | 13,071 |
| 25/24/25 | 5,990 | +6.02% | 7,110 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
Pangen Biotech Inc. is a Korea-based company primarily engaged in the bio pharmaceuticals development technology transfer services. The Company mainly provides contract services for the manufacture of bio pharmaceuticals, bio pharmaceuticals development technology transfer services for the manufacture of Chinese hamster ovary (CHO) cell lines and the process of products and gains royalty from the services. The Company also provides reagents which are used for the development of bio pharmaceuticals. In addition the Company is also engaged in the development of bio pharmaceuticals such as Biosimilar EPO, Recombinant Factor VIII and Biosimilar G-CSF. The Company provides its services within domestic market and to overseas markets such as China, India, Mexico, America and Europe.
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.87% | 51.72M | |
| +26.28% | 42.68B | |
| -3.99% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +6.36% | 24.94B | |
| -21.47% | 18.96B | |
| +27.58% | 12.3B | |
| -2.75% | 11.95B | |
| -2.02% | 11.55B |
- Stock Market
- Equities
- A222110 Stock
